Antimicrobial Resistance and Infectious Complications in Cancer Immunotherapy: CAR-T Cells, Bispecific Antibodies and Immune Checkpoint Inhibitors
International Journal of Molecular Sciences · 05.11.2026 · 27 (21) · 9907
DOI: 10.3390/ijms27219907 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.11.2026. Verfasst von Angioletta Lasagna und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Comprehensive Cancer Center, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Antibodies, Bispecific, Immunotherapy, Adoptive. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies (BsAbs), and immune checkpoint inhibitors (ICIs), have improved outcomes across hematologic and solid malignancies. Infection risk remains heterogeneous and depends on treatment platform, target antigen, lymphodepletion, immune reconstitution, concomitant immunosuppression, and supportive care. This narrative review synthesizes clinical trials, observational studies, and guidance identified through PubMed/MEDLINE, reference screening, and a targeted literature update through October 2026. It focuses on infection incidence, microbiological spectrum, antimicrobial resistance (AMR), multidrug-resistant (MDR) colonization and infection, antimicrobial exposure, prevention, and stewardship. Severe infections can be frequent with BCMA-directed BsAbs: the MagnetisMM-3 study reported grade 3–4 infections in 39.8% of elranatamab-treated patients, while a pooled global teclistamab cohort reported grade 3–4 infections in 55.3%; these estimates are study-specific and are influenced in part by COVID-19. Direct AMR evidence is concentrated in CAR-T and broader cellular-therapy cohorts, while comparable data for BsAbs and ICIs remain limited. Associations between broad-spectrum antibiotic exposure, microbiome disruption, and CAR-T outcomes are clinically important but remain vulnerable to confounding. Prevention should integrate immune status, prior microbiology, antimicrobial exposure, and local resistance patterns rather than infer resistance risk from treatment platform alone. Prospective studies using harmonized outcomes are needed to improve individualized infection prevention and antimicrobial stewardship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Unit, Comprehensive Cancer Center, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
- Department of Systems Medicine, Infectious Disease Clinic, University of Rome Tor Vergata, 00133 Roma, Italy.
- Medical Oncology Department and Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
- Department of Internal Medicine and Medical Therapy, University of Pavia, Strada Nuova, 27100 Pavia, Italy.
ORCID-Profile: Angioletta Lasagna, Paolo Pedrazzoli
Zitieren
APA
Lasagna, A., Andreoni, M., Silvestris, N., & Pedrazzoli, P. (2026). Antimicrobial Resistance and Infectious Complications in Cancer Immunotherapy: CAR-T Cells, Bispecific Antibodies and Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 27(21), 9907. https://doi.org/10.3390/ijms27219907
Vancouver
Lasagna A, Andreoni M, Silvestris N, Pedrazzoli P. Antimicrobial Resistance and Infectious Complications in Cancer Immunotherapy: CAR-T Cells, Bispecific Antibodies and Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. 2026;27(21):9907. doi:10.3390/ijms27219907
BibTeX
@article{Lasagna2026,
author = {Lasagna, Angioletta and Andreoni, Massimo and Silvestris, Nicola and Pedrazzoli, Paolo},
title = {Antimicrobial Resistance and Infectious Complications in Cancer Immunotherapy: CAR-T Cells, Bispecific Antibodies and Immune Checkpoint Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9907},
doi = {10.3390/ijms27219907}
}
EUVIMED